provider for the most current information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information.The recipient will receive more details and instructions to access this offer.By clicking send, you acknowledge that you have permission to email the recipient with this information. Dose range: 5-40 mg once daily. • Dose range: 5-40 mg once daily. Do not take Crestor if you are allergic to rosuvastatin or any ingredients contained in this drug.Keep out of reach of children. Call your doctor for information and medical advice about side effects. It is also used to treat adults who cannot control their cholesterol levels by diet and exercise alone.

Rosuvastatin calcium tablets can be taken at any time of day, with or without food. Copyright © 2018 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment. In addition to eating a proper diet (such as a low cholesterol/low-Rosuvastatin is available under the following different brand names: Indicated to reduce total-C, LDL-C, and ApoB levels in children and adolescents aged 8-17 years if after an adequate trial of diet Indicated to reduce LDL-C, Total-C, nonHDL-C and ApoB in children and adolescents aged 7 to 17 years with homozygous familial hypercholesterolemia, either alone or with other Primary prevention of cardiovascular disease in individuals with no clinically evident heart disease but who are at risk because of combined effect of risk factors listed belowPostmarketing side effects of rosuvastatin reported include:This is not a complete list of side effects and other serious side effects may occur. and formulary information changes. 2500032-overview Use 40 mg dose only for patients not reaching LDL-C goal with 20 mg HoFH: Starting dose 20 mg/day. 2001 Indicated as adjunctive therapy to diet in adults with hypertriglyceridemia, hyperlipidemia, mixed dyslipidemia, or primary dysbetalipoproteinemiaTablets and capsules: 10-20 mg PO qDay; not to exceed 40 mg/dayAfter initiation or upon titration, analyze lipid levels within 2-4 weeks and adjust dosage accordinglyIndicated as adjunctive therapy in adults with homozygous familial hypercholesterolemiaTablets and capsules: 20 mg PO qDay; not to exceed 40 mg/dayAfter initiation or upon titration, analyze lipid levels within 2-4 weeks and adjust dosage accordinglyIndicated as adjunctive therapy to diet to slow the progression of atherosclerosis in adult patients as part of a treatment strategy to lower total cholesterol and LDL cholesterol to target levelsTablets and capsules: 10-20 mg PO qDay; not to exceed 40 mg/dayAfter initiation or upon titration, analyze lipid levels within 2-4 weeks and adjust dosage accordinglyIndicated to reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in individuals without clinically evident coronary heart disease with risk factorsInitiating therapy or switching from another HMG-CoA reductase inhibitor: Start on appropriate dose and then titrate based on patient’s response and individualized goal of therapyLimitation of use: Not studied in Fredrickson type I and V dyslipidemiasInitiating therapy or switching from another HMG-CoA reductase inhibitor: Start on appropriate dose and then titrate based on patient’s response and individualized goal of therapyLimitation of use: Not studied in Fredrickson type I and V dyslipidemiasDepression and sleep disorders (including insomnia and nightmares)Fatal and nonfatal hepatic failure, hepatitis, jaundiceCognitive impairment (eg, memory loss, forgetfulness, amnesia, memory impairment, confusion)Active liver disease (including unexplained persistent elevations of LFTs)Nonserious and reversible cognitive adverse effects may occurIncreased blood glucose and glycosylated hemoglobin (HbA1c) levels reported with statin intake; in some instances, these increases may exceed the threshold for the diagnosis of diabetes mellitusUse caution in patients who consume large amounts of ethanol or have a history of liver diseaseInterrupt therapy if serious hepatotoxicity with clinical symptoms and/or hyperbilirubinemia or jaundice occurs during treatmentIncreases in AST or ALT reported with HMG-CoA reductase inhibitors; monitor liver enzymes before initiating and if signs or symptoms of liver injury occurCases of myopathy and rhabdomyolysis with acute renal failure secondary to myoglobinuria reported with HMG-CoA reductase inhibitors; may occur at any dose level, but are increased at the highest dose (40 mg); caution in patients with predisposing factors for myopathy (eg, age ≥65 years, inadequately treated hypothyroidism, renal impairment)Discontinue treatment if markedly elevated creatine kinase levels occur or myopathy is diagnosed or suspected; temporarily withhold in any patient with an acute, serious condition suggestive of myopathy or predisposing to the development of renal failure secondary to rhabdomyolysis (eg, sepsis; hypotension; dehydration; major surgery; trauma; severe metabolic, endocrine, or electrolyte disorders; uncontrolled seizures)Pharmacokinetic studies demonstrated an ~2-fold elevation in median exposure (AUC and peak plasma concentrations) in Asian subjects when compared with a white control groupRare reports of immune-mediated necrotizing myopathy, characterized by increased serum creatine kinase that persists despite discontinuing statinHematuria and proteinuria reported without decrease in renal function; consider dosage reduction if unexplained hematuria and proteinuria persistsRule out secondary causes of hyperlipidemia prior to initiating therapyBecause HMG-CoA reductase inhibitors decrease cholesterol synthesis and possibly synthesis of other biologically active substances derived from cholesterol (eg, cell membranes), rosuvastatin may cause fetal harm when administered to pregnant womenLimited data indicate that rosuvastatin is present in human milk; because statins have the potential for serious adverse reactions in nursing infants, women who require rosuvastatin treatment should not breastfeed their infantsA: Generally acceptable.